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Background: Epstein-Barr virus (EBV) is an oncogenic virus implicated in the pathogenesis of several human
malignancies. However, due to the lack of a suitable animal model, a number of fundamental questions pertaining
to the biology of EBV remain poorly understood. Here, we explore the potential of rabbits as a model for EBV
infection and investigate the impact of immunosuppression on viral proliferation and gene expression.
Methods: Six healthy New Zealand white rabbits were inoculated intravenously with EBV and blood samples
collected prior to infection and for 7 weeks post-infection. Three weeks after the last blood collection, animals were
immunosuppressed with daily intramuscular injections of cyclosporin A at doses of 20 mg/kg for 15 days and blood
collected twice a week from each rabbit. The animals were subsequently sacrificed and tissues from all major organs
were collected for subsequent analysis.
Results: Following intravenous inoculation, all 6 rabbits seroconverted with raised IgG and IgM titres to EBV,
but viral DNA in peripheral blood mononuclear cells (PBMCs) could only be detected intermittently. Following
immunosuppression however, EBV DNA could be readily detected in PBMCs from all 4 rabbits that survived the
treatment. Quantitative PCR indicated an increase in EBV viral load in PBMCs as the duration of immunosuppression
increased. At autopsy, splenomegaly was seen in 3/4 rabbits, but spleens from all 4 rabbit were EBV PCR positive.
EBER-in situ hybridization and immunoshistochemistry revealed the presence of a large number of EBER-positive
and LMP-1 positive lymphoblasts in the spleens of 3/4 rabbits. To a lesser extent, EBER-positive cells were also seen
in the portal tract regions of the liver of these rabbits. Western blotting indicated that EBNA-1 and EBNA-2 were also
expressed in the liver and spleen of infected animals.
Conclusion: EBV can infect healthy rabbits and the infected cells proliferate when the animals are
immunocompromised. The infected cells expressed several EBV-latent gene products which are probably driving
the proliferation, reminiscent of what is seen in immunocompromised individuals. Further work is required to
explore the potential of rabbits as an animal model for studying EBV biology and tumorigenesis.
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Epstein-Barr virus (EBV) is a human lymphotropic her-
pesvirus implicated in the pathogenesis of a number of
malignancies of both epithelial and lymphoid origin,
including Burkitt’s lymphoma (BL), nasopharyngeal car-
cinoma (NPC), post-transplant lymphoproliferative disease* Correspondence: g_khan@uaeu.ac.ae
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unless otherwise stated.(PTLD) and Hodgkin lymphoma (HL) [1]. A large part
of our current understanding of the biology of EBV
comes from studies of in vitro infection of human
B-lymphocytes. Infection of B-cells leads to their
immortalization [2]. In these cells, the virus estab-
lishes type III latency in which up to 11 viral products,
namely 6 Epstein-Barr nuclear antigens (EBNA-1,
EBNA-2, EBNA-3a, EBNA-3b, EBNA-3c, EBNA-LP),
three virus-encoded latent membrane proteins (LMP-
1, LMP-2a, LMP-2b) and two non-protein encodinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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killing the cell [3,4]. Although the mechanism(s) by
which EBV causes cell immortalization is not clear, it
has been shown that some of these EBV latent proteins
influence, directly or indirectly, a number of key cellular
processes, including inhibition of apoptosis, induction of
cell proliferation and transformation [5-8].
In contrast to in vitro infection, the biology of EBV
infection in vivo is much more complex and less well
understood. The virus is widespread in all human popu-
lations, with over 90% of adults worldwide being infected
[1]. Although it is well known that EBV is transmitted via
the oral route, it is unclear whether B-cells or oropharyn-
geal squamous epithelial cells are the initial sites of infec-
tion. Ironically, even in acute infections where there is
abundant viral presence, only B-cells and not epithelial
cells have been shown to be infected [9-11]. More recent
studies suggest that EBV-infected B-lymphocytes can
transfer EBV to epithelial cells by close interaction
between the two cell types [12,13]. However, the identity
of the virus-producing cells responsible for the infectious
virus present in the saliva [14] remains in doubt. What is
clear is that EBV establishes a life-long persistence in rest-
ing memory B-lymphocytes [15,16]. The frequency of
these cells is tightly regulated in the healthy individuals
[17] and probably evade the host immune response by
down-regulating essential cellular activation molecules
and limiting viral gene expression to one or two proteins
only [18,19]. Disruption of this tightly regulated system, as
seen in allograft recipients receiving immunosuppressive
therapy, can lead to EBV-driven lymphoproliferative disor-
ders (PTLD) [20-23]. In these patients, the frequency of
circulating EBV-infected cells increases dramatically soon
after transplantation and this increase correlates with
the development of B-cell lymphoproliferations [24-26].
However, the precise molecular pathways taken by
EBV-infected cells on their route to the development of
EBV-associated PTLD remains to be demonstrated.
One major obstacle which has hampered research in
unraveling the biology of EBV and its role in the patho-
genesis of EBV-associated diseases has been the lack of
a suitable animal model. Humans are the only natural
host for EBV. EBV is highly cell tropic, infecting only
human B-cells expressing CD21 receptor [27]. B-cells
from animals such as mice or rats cannot be infected
with EBV, in vivo or in vitro. EBV-like herpesviruses
infecting mice [28,29] or primates [30,31] have been
used to study EBV, as have humanized mice [32,33].
These models, albeit useful, have their drawbacks and
do not fully represent natural bona fide EBV infection
in humans. Thus, without a suitable animal model, a
number of fundamental questions about the biology of
EBV and its role in the pathogenesis of human diseases
remain outstanding.Recently, a Japanese group has successfully infected
rabbits with EBV and shown that the virus can persist in
these animals for several years without any major path-
ologies [34-36]. Moreover, it has been shown that EBV
inoculation via intranasal and oral routes can also lead
to persistent EBV infection [34,37]. If these findings can
be independently confirmed, it could open up many
channels for studying the biology of EBV and its link to
the pathogenesis of EBV-associated human diseases. In
this study, we show that rabbits can indeed be infected
with EBV and further show that the infected cells prolifer-
ate under immunosuppressive conditions, similar to what
has been described for allograft recipients on immunosup-
pressive drugs [21,38].
Results
Rabbits respond to EBV upon IV inoculation of the virus
Six healthy male New Zealand white rabbits aged 2–4
months (0.8-1.2 kg) were exposed to EBV by intravenous
injection of 1 ml of cell-free, 0.45 μm filtered culture
supernatant from B95-8 cell line. Each animal was inoc-
ulated 3 times on alternative days. The average EBV copy
number in each inoculum, as determined by quantitative
PCR (qPCR) [39] was estimated to be 1.74 × 107 copies.
The infectivity of the virus in the culture supernatant
was assessed by its ability to successfully immortalize
human PBMCs in vitro [40]. All 6 animals seroconverted
and mounted a strong antibody response, but none
developed any systemic signs of acute EBV infection. As
expected, IgM was the first antibody to be triggered. In
general, IgM levels were highest in week 1 and then
gradually declined to background levels by week 5
(Figure 1A). IgG levels on the other hand were low to
start with, but then increased and remained fairly high
during the 7 weeks follow up (Figure 1B). All the OD
readings were calculated relative to pre-infection plasma.
Interestingly, in one rabbit (Rbt 419), both the IgG and
IgM responses, albeit strong, were delayed compared to
the other animals and peaked at weeks 4 for IgM and 7
for IgG (Figure 1C). The significance of this observation
is not clear, however it is noteworthy that this animal
subsequently developed an extensive and widespread
EBV infection.
Detection of EBV in peripheral blood of rabbits pre- and
post-immunosuppression
For the detection of EBV, PCR was performed on DNA
extracted from PBMCs of blood samples collected at
weekly intervals post-infection from all 6 rabbits. As
expected, no amplification signals were detected in any
of the rabbits pre-infection (Figure 2A). However, 2–7
weeks after infection, weak amplification signals were
detected intermittently in some samples in all 6 rabbits
(Figure 2B). At week 10 post-infection, animals were
Figure 1 Immune responses to EBV. IgM (A) and IgG (B) responses
to EBV infection in 6 healthy rabbits (Rbt 415–420) over a period of
7 weeks post infection. Generally, IgM levels were elevated in the first
week post-infection and then tailed off by week 5. In contrast, IgG
levels gradually increased and remained high up to the 7 weeks follow
up. In one rabbit (Rbt 419), both the IgM and IgG responses to EBV
were delayed compared to the other animals, peaking at week 4 for
IgM and week 7 for IgG (C). The data presented here is for plasma at
dilution 1/100. Similar patterns were seen with plasma diluted 1/200
and 1/400, but with lower OD values.
Figure 2 Detection of EBV in rabbit PBMCs pre- and post-infection.
EBV BamH1 W PCR (amplicon size: 152 bp) was performed on DNA
extracted from PBMCs collected from rabbits at various stages of
infection: Pre-infection (A); at week 3 post-infection (B) and at week 13
post-infection (C) (the last 15 days of which the animals were treated
with daily injections of 20 mg/Kg of cyclosporin A (CsA) for 15 days).
None of the animals were EBV positive prior to inoculation (A). At week
3 post-infections, weak amplifications were seen in all 6 animals (B).
However, EBV positivity was intermittent and many of the samples taken
at other time periods were negative. Following CsA treatment, all 4
rabbits that survived the 15-day CsA treatment were clearly EBV positive
(C). Furthermore, EBV positivity correlated with immunosuppression
(D). A representative data for rabbit 416 is provided as an example.
EBV positivity was only seen about one week after the start of the
immunosuppressive treatment. Positive (+) and negative controls (−) are
indicated (see methods for further details).
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(CsA) for a period of 15 days [41,42]. One of the animals
(Rbt 417) died overnight after the first CsA injection due
to widespread fungal infection. A second animal (Rbt 418)
was found to be very lethargic, not eating and generally
looking unwell. This animal also had evidence of fungalinfection. On the advice of the veterinarian and following
the animal ethics guidelines, the animal was sacrificed
before the second dose of CsA. Tissues from all major
organs were collected from both rabbits. The remaining 4
animals survived the 15 day immunosuppressive treat-
ment and we were able to collect blood samples at regular
Figure 3 Determination of viral load and viral gene expression
following immunosuppression. A EBV viral load in PBMCs (copies/
μg DNA) was determined using qPCR. Three independent experiments
were carried out for each sample at each interval post-cyclosporin
A (CsA) treatment. The mean values, together with the standard
deviations are presented. Viral load clearly increased with increasing
duration of immunosuppression. No EBV was detected pre-infection
(Pre-I) or in the first few days post-CsA treatment of EBV infected
animals. B Reverse transcriptase PCR for EBV EBNA-1, EBNA-2, BZLF,
and LMP-1 was performed on RNA extracted from PBMCs of rabbits
at various time intervals following daily treatment with CsA. Weak and
intermittent expression of several EBV genes was detected towards the
end of the CsA treatment period. Positive (+) and negative (−) controls
and the size of each amplicon are indicated.
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from blood samples taken post-immunosuppression gave
strong amplification signals for EBV. This was particularly
notable for blood samples taken on day 15 of treatment
(Figure 2C). Viral load appeared to increase with increas-
ing duration of immunosuppression (Figure 2D). This was
then examined further using quantitative PCR (qPCR)
(see ahead).
Determination of EBV viral load and viral gene expression
in peripheral blood of rabbits during immunosuppression
Using qPCR and Namalwa cell line DNA as standards
[39], we determined EBV viral load in PBMCs collected
from rabbits during the 15 day CsA immunosuppressive
treatment (Figure 3A). Analogous to post-transplant
patients on immunosuppressive therapy, EBV viral load
increased with increasing duration of immunosuppres-
sive treatment [24,26]. The highest viral loads were
noted in samples collected at day 15 of treatment. Prior
to treatment, EBV was undetectable in 50 ng of PBMCs
DNA that was used in each qPCR reaction (Figure 3A).
Analysis of EBV gene expression using reverse tran-
scriptase PCR (RT-PCR) indicated that several EBV
latent genes were expressed in PBMCs, notably towards
the end of the 15 day CsA treatment period (Figure 3B).
EBV gene expression was variable; EBNA-1 and EBNA-2
were clearly expressed by day 15 whilst the expression of
BZLF and LMP-1 was at best weak and intermittent.
The expression of the lytic marker BZLF, albeit intermit-
tent, suggests that some lytic replication may be occurring
during immunosuppression.
Autopsy and macroscopic findings
The 4 rabbits that survived the 15-day CsA treatment
were euthanized and sacrificed on day 17 and tissues
from all major organs collected. At autopsy, splenomegaly
was noted in 3 of the 4 rabbits. This was most prominent
in rabbit 419, which also had hepatomegaly (Figure 4A).
DNA extracted from spleen samples gave strong positive
signals for EBV (Figure 4B). The signals were stronger for
the 4 rabbits that survived the 15-day CsA treatment com-
pared to the two rabbits (Rbt 417 and 418) that died early
on during the treatment period. PCR for EBV was per-
formed using 2 different sets of BamH1 W primers giving
amplification products of 152 bp and 552 bp. Both primer
sets gave similar results. qPCR on splenic DNA further
confirmed these findings (Figure 4C).
Detection of EBV in autopsy tissues of rabbits
EBER-in situ hybridization (EBER-ISH) was performed
on formalin-fixed, paraffin-embedded sections of rabbit
autopsy tissues to detect the virus and its tissue distribu-
tion as previously described [43,44]. All major organs
were examined, but positive signals were only seen inthe spleen and liver of 3 rabbits (Rbt 415, Rbt 416 and
Rbt 419) (Figure 5A). No staining was seen in rabbit 420
and in the two rabbits (Rbt 417 and Rbt 418) that died at
the start of the CsA treatment. Of the 3 EBER-ISH posi-
tive spleens, the most extensive and widespread infection
was seen in rabbits 416 and 419 and the least in rabbit
415 (Figure 5A). These observations were consistent with
the qPCR findings on PBMCs and spleen tissues from
Figure 4 Hepatosplenomegaly in rabbit 419. Splenomegaly
was noted at autopsy in 3 of the 4 rabbits that survived the 15 day
cyclosporin A (CsA) treatment. In rabbit 419, both the spleen and
liver were enlarged (A). EBV BamH1 W PCR on DNA extracted from
rabbit spleens indicated that all were EBV positive (B). Amplification
signals were stronger in the spleens of the 4 animals that survived
the 15 day immunosuppressive treatment compared to the 2
animals (Rbt 417 and Rbt 418) that died on day 2 after the start of
the CsA treatment. Similar results were observed using two different
sets of EBV BamH1 W primers (amplicon size of 552 bp and 152 bp).
Quantitative PCR analysis (C) confirmed the standard end-point PCR
findings observed in Figure 4B.
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sections from the same spleen, treated and processed at
the same time and in exactly the same way, except that
non-complementary sense probes were used, consistently
gave negative staining (Figure 5B). The EBER-staining pat-
tern was characteristically nuclear with nucleolar sparing,
typical of EBER-ISH [43,44]. Morphologically, the infected
cells were large lymphocytes. For rabbit 415, the infectedcells in the spleen were restricted to one location which
resembled a large lymphoid nodule (Figure 6A). The same
nodule was also positive for LMP-1 (Figure 6B). It is
possible that this lymphoid nodule is a consequence
of EBV-induced proliferation of infected lymphocytes.
Histologically, the nodule appeared to be of inflammatory
nature and not malignant. As for the liver, EBER-ISH posi-
tive cells were located almost exclusively in the portal tract
regions (Figure 7). There was no histological evidence of
any significant inflammation of the liver or infection of
hepatocytes in any of the 3 infected rabbits. Rabbit 419
had the most extensive infection. In fact, only scattered
EBER-ISH positive cells could be seen in rabbits 415 and
416. Apart from a few scattered EBV-positive cells seen in
the lung of rabbit 419, no evidence of EBV infection was
noted in any other tissues (lung, heart, kidneys), in any of
the other rabbits.
Detection of EBV gene expression in the spleen and liver
of infected rabbits
Spleen and liver tissues from the 3 rabbits (Rbt 415, Rbt
416, Rbt 419) which were found to be EBV positive by
EBER-ISH were examined for LMP-1 expression using
immunohistochemistry. Spleen sections from all 3 rab-
bits were found to have positive cells (Figure 8A) and
they were distributed in the same regions as the EBER-
ISH positive cells. Indeed, the one large lymphoid nod-
ule that was EBER-ISH positive in the spleen of rabbit
415 was also LMP-1 positive. The pattern of LMP-1
staining was both membrane and cytoplasmic. Overall,
the number of LMP-1 positive cells was distinctly less
than the number of EBER-ISH positive cells for the same
tissue. In the liver, LMP-1 positive cells were sparsely
scattered, even for rabbit 419 (data not shown). Western
blotting for EBNA-1 and EBNA-2 revealed that both
were expressed in the spleen and liver of EBER-ISH
positive animals (Figure 8B). These observations are
similar to the RT-PCR results for the expression of these
genes in PBMCs (Figure 3B).
Discussion
It is just over 50 years since EBV was first isolated from
a case of Burkitt’s lymphoma. Although much progress
has been made over the decades, some basic aspects of
EBV biology such as the initial cellular target of primary
infection, the cellular source of the virus detected in
saliva during persistent infection, and the detailed mech-
anisms by which this virus induces tumorigenesis is
poorly understood. The lack of a suitable laboratory
model is certainly one of the contributing factors for the
slow progress in these areas. EBV is a highly species spe-
cific virus, infecting humans only, with B-lymphocytes
being its primary cellular target. Other γ-herpesviruses
closely related to EBV have been shown to naturally
Figure 5 EBER-in situ hybridization for the detection of EBV in the spleens of infected rabbits. EBV infected cells were present in the
spleens of 3 of the 4 rabbits that survived the 15 day CsA treatment (Panel A). Rabbits 416 and 419 had the most extensive infection. EBER-positive cells
were heavily distributed in most parts of the spleens of these animals. No staining was seen in the corresponding negative controls (Panel B).
Figure 6 Detection of EBV and EBV gene expression in a large lymphoid nodule in the spleen of rabbit 415. In rabbit 415, EBER positive
cells in the spleen were localized to one large lymphoid nodule (A). The same nodule was also positive for LMP-1 (B). Both, EBER-in situ hybridization
and LMP-1 immunohistochemistry were repeated 2 more times on consecutive sections and the same nodule was EBV positive.
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Figure 7 Detection of EBV in the liver of rabbit 419. Scattered
EBER-positive cells were noted in the liver of all 3 animals that survived
the cyclosporin A treatment. However, the EBER-positive cells were
limited in number and dispersed within the portal tract regions only and
there was no evidence of infection of hepatocytes (A). Morphologically,
EBER-positive cells were typically large lymphocytes (B). Negative controls
using sense probe were consistently negative (C).
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[46,47] and they have been used as models to under-
stand EBV infection and pathogenesis. However, the
major drawback with these animal models is that they
do not entirely represent EBV infection in humans.
Recently, a Japanese group reported that rabbits
(Japanese White) were susceptible to EBV infection and
manifest features reminiscent of EBV infection in humans
[48,34,36]. In the present study we confirm that healthyrabbits (New Zealand White) can indeed be infected with
EBV via intravenous inoculation and the virus persists in
peripheral blood lymphocytes of infected animals. We
further show that rabbits mount a strong immune re-
sponse to the virus, as evident by the raised levels of IgM
and IgG in the plasma. The immune system is most likely
to be the central force responsible for clearing the virus
and limiting viral replication and spread. This is supported
by our findings of low level viral DNA and little or no
gene expression in peripheral blood mononuclear cells
(PBMCs) in the 7 week follow up post EBV infection. This
is similar to what is generally seen in healthy EBV sero-
positive individuals [17,18]. However, following immuno-
suppression with daily injections of cyclosporin A, EBV
viral load in PBMCs increased from undetectable levels to
tens of thousands of copies by day 15 of treatment. The
increase in viral load correlated with increasing duration
of immunosuppression. These results were also consistent
with qPCR data for EBV viral load in the spleens of the 4
rabbits that survived CsA treatment. Moreover, EBER-ISH
revealed the presence of abundant EBV infected cells in
the spleens of 3 of 4 rabbits, but not in the two rabbits
that died on day 2 of CsA treatment. These findings
suggest that under immunosuppressive conditions, EBV
infected cells can proliferate, analogous to what has been
reported in post-transplant recipients on CsA immuno-
suppressive therapy [20,24,38,49]. We also noted the
expression of LMP-1, EBNA-1 and EBNA-2 in EBV posi-
tive spleens. In PBMCs however, the level of expression of
some of these genes was weak and intermittent. Previous
studies on EBV gene expression in PBMCs from post-
transplant recipients have reported conflicting results.
Some studies have reported that EBV gene expression is
restricted and similar to that seen in healthy carriers
[25,50], whilst others have reported that the EBV gene
expression pattern is more broader [49,51]. Interestingly,
tumor tissues from allograft recipients tend to express
type III latency [21-23]. It is possible that EBV gene ex-
pression varies at different stages of differentiation of the
EBV-infected cells on their route to tumor development
[38,52,53]. The pattern of EBV gene expression is also
likely to be dictated by the degree and length of immuno-
suppression [24].
In contrast to the spleen, EBV infection of the liver in
these animals was noticeably less. Only scattered EBER-
ISH positive cells could be detected and they were re-
stricted to the portal tract regions. There was no evidence
of infection of hepatocytes or infiltration of EBV-infected
lymphocytes into the liver parenchyma. Morphologically,
infected cells resembled lymphoblast. We also noted that
there was a correlation between the severity of infection in
the spleen and the frequency of infected cells in the liver.
Rabbit 419, which had the most extensive infection in the
spleen, also had the highest frequency of infected cells in
Figure 8 Detection of EBV expression in the spleen and liver of EBV infected rabbits. All EBER-positive spleens were tested for the expression
of EBV LMP-1 by immunohistochemistry (A). Characteristic membrane and cytoplasmic staining was evident in the spleen of all 3 rabbits (A) bottom
panel. Formalin-fixed and paraffin-embedded EBV-positive cell line B95-8 was used as positive control. Expression of EBNA-1 and EBNA-2 was examined
by western blotting (B). A total of 50 μg of protein lysate was loaded per well. Specific bands were noted in both the liver (L) and spleen (S) of infected
animals. Protein extracts from B95-8 cells was used as positive control.
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in the lungs of rabbit 419. It remains to be demonstrated
whether the peripheral circulation or lymphoid tissues
is the main site for proliferation of EBV infected cells.
Quantitative EBV PCR on PBMCs and spleens at day
15 of immunosuppression showed a higher viral load in
the spleens compared to PBMCs in 3/4 rabbits, indicat-
ing that lymphoid tissues such as the spleen maybe the
preferred site. Furthermore, the finding of abundant ex-
pression of LMP-1 in the spleen, but not in the PBMCs
of infected animals, also supports lymphoid tissues as
the most likely site for EBV proliferation [54]. In the
lymphoid tissues, EBV infected cells probably enter the
germinal centers where viral and local tissue factors
could mediate their proliferation and expansion [55,56].
On differentiation into memory cells expressing little or
no viral genes, the infected cells could then enter the
peripheral circulation [50]. The rabbit model described
here could help to further delineate the dynamics of
EBV infection and mechanism of proliferation.Conclusion
In conclusion, we confirm that healthy rabbits can be
infected with EBV and immunosuppression can induce
EBV proliferation similar to what has been observed in
transplant recipients. Rabbits may prove to be a conveni-
ent and suitable small animal model for the study of
EBV infection. For example, determining which cells are
first infected following salivary transmission of the virus
and the subsequent cellular dynamics leading to the life-
long latency typical of EBV would be a significant devel-
opment in our understanding of the pathophysiology of
EBV. Rabbit model could also prove to be useful for




Six healthy male New Zealand white rabbits (0.8-1.2 kg)
aged 2–4 months were purchased from a local animal
facility and housed in the Animal House of the College
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accordance with institutional policies. The project was
reviewed and approved by our Institutional Review Board
and experiments were performed in accordance with
protocols approved by the Animal Research Ethics Com-
mittee of UAE University (Approval number A14-12).
Preparation of EBV for infection of rabbits
B95-8 cells (EBV producer cell line) [2] were cultured in
RPMI-1640 (GIBCO, USA), supplemented with 10% FBS
(GIBCO, USA), 1% antibiotic antimycotic solution (Santa
Cruz, UK), 50 μg/ml gentamycin (Hyclone, USA) and 1×
glutamine (GIBCO, USA), as previously described [58].
Cells were cultured until they reached a density of ap-
proximately 5×106 cells/ml. Culture supernatants were
centrifuged to remove cells/cell debris and then filtered
using a 0.45 μm filter. Fresh filtered virus preparations
were used for inoculation of rabbits. EBV copy number in
the inoculum was estimated using quantitative real-time
PCR (qPCR) (see ahead). The infectivity of the virus was
determined by in vitro immortalization of human PBMCs
[40]. This was approved by the Al Ain Medical District
Human Research Ethics Committee (Approval number
AAMD HREC 14/13).
Inoculation of rabbits with EBV and immunosuppression
Pre-inoculation blood samples were collected from the
ear marginal vein of all rabbits. For EBV infection, animals
were injected intravenously with 1 ml of fresh culture
supernatant filtrate. EBV inoculation of rabbits was
repeated on day 3 and 6 after the first injection. Approxi-
mately 4 ml of blood was collected into heparin tubes (BD
Bioscience, UK) from each animal on weekly basis for a
total of 7 weeks. The heparinized blood was diluted 1:1 in
RPMI 1640 media and layered (under sterile conditions)
over Histopaque 1083 (Sigma, UK) and centrifuged at
600 g for 20 minutes in a bench top X15R centrifuge
(Beckman Coulter, UK). The plasma and peripheral
blood mononuclear cell (PBMC) fractions were care-
fully collected into separate tubes. PBMCs were washed
with PBS (x2), cell number determined by trypan blue
dye exclusion and then stored at −80°C. Plasma samples
were stored at −40°C.
At week 10 post-infection, animals were started on
immunosuppressive therapy with daily subcutaneous
injection of 20 mg/kg of cyclosproin A (CsA) (Sandim-
mume -Novaratis) [41,42] for a total of 15 days. Animals
were monitored daily by a veterinarian for signs of CsA
toxicity, such as drooling, diarrhea, lack of food intake
and weight loss [59]. Any animal that became seriously
sick was sacrificed in accordance with the ethics guide-
lines. Blood was collected on days 1, 4, 8, 11 and 15 after
commencement of immunosuppressive therapy. On day
17, surviving animals were euthanized and autopsied.Tissue samples from all major organs, including spleen,
liver, kidneys, heart and lungs were collected. One piece
from each organ was immediately snap-frozen in liquid
N2 for DNA/RNA extraction and one piece was imme-
diately fixed in 10% formalin for histology, in situ
hybridization and immunohistochemistry.
Testing for EBV antibodies in rabbit plasma
EBV specific antibodies in rabbit plasma samples were
measured using a modified Enzyme linked immunosorb-
ent assay (ELISA) [60]. Briefly, 96 well ELISA plates
(Nunc, Denmark) were coated with proteins from EBV-
infected B95-8 cell line. Each well was coated with
100 ng of proteins with overnight incubation. Rabbit
plasma at different dilutions (1/100, 1/200, 1/400) was
applied to the wells and bound antibodies subsequently
detected using goat anti-rabbit IgG (Cell Signaling,
USA) or goat anti-rabbit IgM secondary antibody conju-
gated to HRP (Abcam, UK). After adding the TMB sub-
strate and allowing the colour to develop for 5 minutes
in the dark, the reaction was stopped and OD450 mea-
sured using an ELISA reader (Gen 5 BioTek, USA). All
the OD450 values were read against the pre-inoculation
plasma samples from the same rabbit. All tests were
done in duplicates and the mean values were used in
further analysis.
PCR for the detection of EBV in peripheral blood
DNA was extracted from rabbit PBMCs and autopsy
tissues using standard phenol-chloroform extraction
methodology as previously described [61]. The quantity
and purity of the extracted DNA was determined using
the Nanodrop-1000 instrument (Nanodrop Technologies,
USA). PCR was performed on 100 ng of extracted DNA
using primers specific for EBV BamHI W fragment [62].
Amplification of ‘house-keeping gene’ β-globin [63] was
performed to assess the integrity of the DNA. Each PCR
run of 35 cycles included a positive control (DNA from
B95-8 cell line) and a negative control (water). PCR
reactions were carried out using an Applied Biosystems
thermal cycler GeneAmp® PCR System 2700. Amplified
products were visualized on 2.5% agarose gel stained with
ethidium bromide.
Quantitative real-time PCR (qPCR) for determination of
EBV viral load
EBV copy number in the initial inoculum and subse-
quently in the PBMCs/spleen tissues was estimated using
qPCR targeting EBV BamH1W region and Namalwa cell
line DNA standards, as previously described [39]. Briefly,
for each qPCR reaction, 50 ng of template DNA was used
in a total reaction volume of 20 μl with ABS TaqMan Uni-
versal Master mix along with TaqMan probe. All samples
were tested in duplicates or triplicates in a 40 cycle
Khan et al. Virology Journal  (2015) 12:28 Page 10 of 12reaction using Applied Biosystem 7500 real time PCR
machine. All qPCR experiments were independently re-
peated 3 times and the mean copy number and standard
deviation calculated for each sample.
EBER-in situ hybridization for the detection of EBV in tissues
The presence of EBV in autopsy tissues was determined
by using a very sensitive and highly specific technique
of EBER-in situ hybridization, essentially as previously
described [43,44]. Briefly, EBER-in situ hybridization
was performed on 5-μm sections of formalin-fixed,
paraffin-embedded tissue sections using a mixture of
digoxigenin-labeled EBER-1 and EBER-2 probes with
overnight hybridization. Hybridized probes were subse-
quently detected using mouse anti-digoxin monoclonal
antibody at a dilution of 1/2500 (Sigma, UK) and the
ABC-peroxidase method (Ultra-Sensitive ABC-Peroxidase
Staining kit, Thermo Scientific, USA). Diaminobenzidine
tetrahydrochloride (DAB) (Sigma, UK) was used as the
chromogen. With each batch of tissue sections, a positive
control (EBV-infected B95-8 cells or EBV-lymphoblastoid
cell lines) and a negative control (using digoxigenin-
labeled non-complimentary EBER probes) was included.
Reverse transcription (RT)-PCR for the detection EBV gene
expression in PBMCs
Total RNA was extracted from rabbit PBMCs using TRIzol
reagent (Invitrogen) and quantified using the Nanodrop
instrument. 1 μg of RNA was reverse transcribed to cDNA
using the Reverse Transcription System (Promega) follow-
ing the manufacturer’s instructions. Before reverse tran-
scription, all RNA samples were treated with DNase I
(Promega, USA) to remove any contaminating genomic
DNA. RT-PCR was performed to determine the expression
of EBNA-1, EBNA-2, LMP-1 and BZLF-1 using primers
and conditions previously described [64]. Amplification of
‘housekeeping gene’ GAPDH was used as an internal
positive control [65]. All RT-PCR reactions consisted of
35 cycles with a final elongation at 72°C for 10 minutes.
Immunohistochemistry and western blotting for the
detection of EBV gene expression
Expression of EBV LMP-1, EBNA-1, and EBNA-2 in rabbit
tissues was assessed by immunohistochemistry and/or
western blotting. Immunohistochemistry was performed on
5 μm sections of formalin-fixed paraffin embedded rabbit
spleen and liver tissues using LMP-1-specific monoclonal
antibodies (clone CS1-4) (Abcam, UK) at 1/100 dilution
and the ABC-peroxidase/DAB detection system. Western
blotting was performed on 50 μg of protein extracts from
rabbit spleen and liver tissues. The following monoclonal
antibodies were used: anti-EBNA-1 (clone 0211 - Thermo
Scientific) and anti-EBNA-2 (clone PE2 - Abcam) at dilu-
tions of 1/50 and 1/200 respectively.Competing interests
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